AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16293984 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy Volunteers)
Number of subjects: 66
Study 12439520 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole treatment
Number of subjects: 0
Study 12439520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10531891 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis child care program
Number of subjects: 0
Study 7772426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 15 micrograms kg‐1 h‐1
Number of subjects: 14
Study 7772426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 micrograms kg‐1 h‐1
Number of subjects: 14
Study 7772426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (both doses)
Number of subjects: 14
Study 2789070 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg four times daily (9 doses)
Number of subjects: 18
Study 2789070 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg four times daily with ethamsylate 500 mg before each dose
Number of subjects: 18
Study 2789070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 318741 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylic ester of p-hydroxybenzoic acid (PEPH)
Number of subjects: 45
Study 318741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31499050 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise with blood flow restriction (AE + BFR: 40% VO2max)
Number of subjects: 22
Study 31499050 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE: 80% and 40% VO2max)
Number of subjects: 22
Study 31499050 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (AE: 40% VO2max)
Number of subjects: 22
Study 28110112 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal (IR) added to components of CBT for Insomnia (IR + cCBT-I)
Number of subjects: 94
Study 28110112 — intervention group
Group type: COMPARATOR
Intervention: cCBT-I alone
Number of subjects: 94
Study 25690515 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer-drinking strategies endorsed and implemented (e.g., eating prior to and during drinking, spacing drinks, reducing alcohol consumption)
Number of subjects: 31
Study 24428305 — intervention group
Group type: COMPARATOR
Intervention: Conventional weight‐based dosing of GH (0.04 mg/kg/day)
Number of subjects: 172
Study 24428305 — intervention group
Group type: EXPERIMENTAL
Intervention: GH dosing titrated to an IGF‐I target of 0 SDS (IGF0T)
Number of subjects: 172
Study 24428305 — intervention group
Group type: EXPERIMENTAL
Intervention: GH dosing titrated to an IGF‐I target of +2 SDS (IGF2T)
Number of subjects: 172
Study 23097066 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every six months
Number of subjects: 7808
Study 23097066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808
Study 23097066 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Number of subjects: 7808
Study 19419595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/d)
Number of subjects: 599
Study 19419595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-120 mg/d)
Number of subjects: 599
Study 19419595 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5-20 mg/d)
Number of subjects: 599
Study 17369558 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach-controlled rehabilitation program
Number of subjects: 241
Study 17369558 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 241
Study 15180022 — intervention group
Group type: EXPERIMENTAL
Intervention: neomycin/polymyxin B/hydrocortisone
Number of subjects: 0
Study 15180022 — intervention group
Group type: COMPARATOR
Intervention: ofloxacin
Number of subjects: 0
Study 15180022 — intervention group
Group type: EXPERIMENTAL
Intervention: neomycin/polymyxin B
Number of subjects: 0
Study 11673335 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal-balloon protection system (GuardWire)
Number of subjects: 76
Study 11673335 — intervention group
Group type: COMPARATOR
Intervention: No distal protection (Control)
Number of subjects: 76
Study 9541034 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked cocaine (up to 405 mg over 5 hours daily) for 4 days
Number of subjects: 9
Study 9541034 — intervention group
Group type: COMPARATOR
Intervention: Drug-free period (2 days before and after cocaine administration)
Number of subjects: 9
Study 8017448 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg at bedtime
Number of subjects: 142
Study 8017448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 2525415 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hepatic artery and intravenous infusion of FUDR (IA/IV group; 21 patients)
Number of subjects: 64
Study 2525415 — intervention group
Group type: COMPARATOR
Intervention: Hepatic artery infusion alone (IA group; 23 patients)
Number of subjects: 64
Study 2525415 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IA and IA/IV groups
Number of subjects: 64
Study 2525415 — intervention group
Group type: COMPARATOR
Intervention: IA group
Number of subjects: 64
Study 2525415 — intervention group
Group type: EXPERIMENTAL
Intervention: IA/IV group
Number of subjects: 64
Study 2525415 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (n = 32)
Number of subjects: 64
Study 2525415 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders (n = 32)
Number of subjects: 64
Study 380735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal metronidazole given over a 48-hour period before surgery
Number of subjects: 102
Study 380735 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 102
Study 31864674 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver grafts with steatosis
Number of subjects: 151
Study 31864674 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver grafts with high baseline steatosis (> 40%)
Number of subjects: 151
Study 31864674 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver grafts with moderate baseline steatosis (20%-39%)
Number of subjects: 151
Study 31864674 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver grafts with low baseline steatosis (< 20%)
Number of subjects: 151
Study 26525562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2159
Study 26525562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2159
Study 26061874 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-Q
Number of subjects: 80
Study 26061874 — intervention group
Group type: EXPERIMENTAL
Intervention: AmbuAura-i
Number of subjects: 80
Study 23872647 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY (bioabsorbable polymer everolimus-eluting stent)
Number of subjects: 291
Study 23872647 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY ½ dose
Number of subjects: 291
Study 23872647 — intervention group
Group type: COMPARATOR
Intervention: PROMUS Element (durable polymer everolimus-eluting stent)
Number of subjects: 291
Study 23872647 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY
Number of subjects: 291
Study 23872647 — intervention group
Group type: COMPARATOR
Intervention: PROMUS Element (PE)
Number of subjects: 291
Study 21411610 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) ingestion (30 to 80 g/h, not exceeding 8%) during exercise
Number of subjects: 50
Study 19280938 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 13894
Study 19280938 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 13894
Study 17664405 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg daily
Number of subjects: 343
Study 17664405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 15053236 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromogranin A (CgA)
Number of subjects: 68
Study 15053236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide (PP)
Number of subjects: 68
Study 15053236 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined assessment of CgA and PP
Number of subjects: 68
Study 10890482 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (1 microg/kg/min for 24 hours)
Number of subjects: 20
Study 10890482 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 20
Study 9351079 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10mg/day; n = 25)
Number of subjects: 43
Study 9351079 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (6 g/day; n = 18)
Number of subjects: 43
Study 8095507 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg three times daily)
Number of subjects: 15
Study 8095507 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (30 mg three times daily)
Number of subjects: 15
Study 8095507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8095507 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (used for sympathetic blockade)
Number of subjects: 15
Study 3812100 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of Azatadine
Number of subjects: 16
Study 3812100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold, dry air (CDA) exposure
Number of subjects: 16
Study 11287022 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) hCG administration
Number of subjects: 21
Study 11287022 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) hCG administration
Number of subjects: 21
Study 11287022 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SC and IM hCG administration
Number of subjects: 21
Study 31160181 — intervention group
Group type: EXPERIMENTAL
Intervention: Humming Crescendo Task (HCT)
Number of subjects: 17
Study 31160181 — intervention group
Group type: COMPARATOR
Intervention: Vowel Crescendo Task (VCT)
Number of subjects: 17
Study 30808245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary change intervention
Number of subjects: 20180
Study 30808245 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20180
Study 30224390 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (aldesleukin; dose range 0.3-3×10^6 IU)
Number of subjects: 57
Study 30224390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 25959738 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-adaptation of the dorsolateral peritoneal layer (group A)
Number of subjects: 200
Study 25959738 — intervention group
Group type: COMPARATOR
Intervention: No re-adaptation of the dorsolateral peritoneal layer (group B)
Number of subjects: 200
Study 24129948 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2peak
Number of subjects: 39
Study 24129948 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2VT
Number of subjects: 39
Study 24129948 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity
Number of subjects: 39
Study 22539781 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion perception training
Number of subjects: 0
Study 22539781 — intervention group
Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 0
Study 19934777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrafem
Number of subjects: 159
Study 19934777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 17581445 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT + sertraline
Number of subjects: 24
Study 17581445 — intervention group
Group type: COMPARATOR
Intervention: TF-CBT + placebo
Number of subjects: 24
Study 15608430 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 or 4 mg daily
Number of subjects: 25
Study 15608430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12490338 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD Checklist (PCL) with a cut score of 30
Number of subjects: 1225
Study 12490338 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD Checklist (PCL) with a cut score of 45
Number of subjects: 1225
Study 10458396 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid treatment with improved hygiene
Number of subjects: 318
Study 10458396 — intervention group
Group type: COMPARATOR
Intervention: Gentle retraction and personal hygiene (Control)
Number of subjects: 318
Study 10458396 — intervention group
Group type: EXPERIMENTAL
Intervention: Buried penis subgroup
Number of subjects: 318
Study 7822521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine (2.5 mg/kg/day, adjusted to 5.0 mg/kg/day)
Number of subjects: 210
Study 7822521 — intervention group
Group type: COMPARATOR
Intervention: Etretinate (0.5 mg/kg/day, adjusted to 0.75 mg/kg/day)
Number of subjects: 210
Study 7822521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine replaced by topical dithranol (anthralin)
Number of subjects: 210
Study 7822521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine tapered
Number of subjects: 210
Study 7822521 — intervention group
Group type: COMPARATOR
Intervention: Etretinate followed by topical dithranol
Number of subjects: 210
Study 2358267 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen cooled cryoprobe
Number of subjects: 15
Study 2358267 — intervention group
Group type: COMPARATOR
Intervention: CO2‐cooled cryoprobe
Number of subjects: 15
Study 347990 — intervention group
Group type: EXPERIMENTAL
Intervention: Sch 1000 aerosol
Number of subjects: 23
Study 30746642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Visit Prioritization email intervention
Number of subjects: 1276
Study 30746642 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1276
Study 27015911 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil (VOO)
Number of subjects: 20
Study 27015911 — intervention group
Group type: EXPERIMENTAL
Intervention: Seed Oil with Natural Antioxidants (SOP)
Number of subjects: 20
Study 27015911 — intervention group
Group type: COMPARATOR
Intervention: Sunflower Oil (SFO)
Number of subjects: 20
Study 27015911 — intervention group
Group type: COMPARATOR
Intervention: Mixed Seed Oil with Added Dimethylpolysiloxane (SOX)
Number of subjects: 20
Study 25819853 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg once daily plus clopidogrel 75 mg daily for 12 months
Number of subjects: 2100
Study 25819853 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 2100
Study 25819853 — intervention group
Group type: COMPARATOR
Intervention: Dose-adjusted vitamin K antagonist (VKA) once daily
Number of subjects: 2100
Study 24083174 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 123
Study 24083174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity
Number of subjects: 123
Study 24083174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic heart disease (IHD)
Number of subjects: 123
Study 24083174 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-proliferative diabetic retinopathy
Number of subjects: 123
Study 24083174 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 123
Study 21306433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincter of Oddi (SO) manometry by choledochoscope
Number of subjects: 51
Study 21306433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 51
Study 19899575 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard coaxial phacoemulsification
Number of subjects: 30
Study 19899575 — intervention group
Group type: EXPERIMENTAL
Intervention: Microincisional cataract surgery (MICS)
Number of subjects: 30
Study 18210897 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-only
Number of subjects: 59
Study 18210897 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 59
Study 18210897 — intervention group
Group type: COMPARATOR
Intervention: Calcium-only
Number of subjects: 59
Study 15551207 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination vaccine (RSV cpts‐248/404 and PIV3‐cp45), 10(5) plaque‐forming units of each per 0.5‐mL dose
Number of subjects: 33
Study 15551207 — intervention group
Group type: COMPARATOR
Intervention: Monovalent PIV3 vaccine
Number of subjects: 33
Study 15551207 — intervention group
Group type: COMPARATOR
Intervention: Monovalent RSV cpts‐248/404 vaccine
Number of subjects: 33
Study 15551207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (combination and monovalent)
Number of subjects: 33
Study 11213068 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-dose aprotinin
Number of subjects: 93
Study 11213068 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 93
Study 11213068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 9407422 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile of baseline proteinuria (< 2.5 g/24 hr)
Number of subjects: 274
Study 9407422 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle tertile of baseline proteinuria (2.5 to 4.3 g/24 hr)
Number of subjects: 274
Study 9407422 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of baseline proteinuria (> 4.3 g/24 hr)
Number of subjects: 274
Study 8504651 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (4 mg/kg bolus followed by 2.5 mg/kg every 6 hrs x three doses, then 1.5 mg/kg every 6 hrs)
Number of subjects: 20
Study 8504651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2890820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping with the bed-head raised
Number of subjects: 71
Study 2890820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine therapy
Number of subjects: 71
Study 2890820 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sleeping with the bed-head raised and ranitidine therapy
Number of subjects: 71
Study 2890820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 29016543 — intervention group
Group type: EXPERIMENTAL
Intervention: 33-gauge needle
Number of subjects: 318
Study 29016543 — intervention group
Group type: COMPARATOR
Intervention: 30-gauge needle
Number of subjects: 318
Study 26614597 — intervention group
Group type: EXPERIMENTAL
Intervention: ibandronate 1 mg/month
Number of subjects: 1134
Study 26614597 — intervention group
Group type: COMPARATOR
Intervention: risedronate oral 2.5 mg/day
Number of subjects: 1134
Study 26775516 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg ergometry exercise of 80% peak Watt for 30 minutes per day, 3 days per week for 12 weeks
Number of subjects: 30
Study 26775516 — intervention group
Group type: COMPARATOR
Intervention: Control group without exercise
Number of subjects: 30
Study 23453789 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZRS)
Number of subjects: 225
Study 23453789 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 225
Study 23453789 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 225
Study 21467949 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.1 mmol/kg BW
Number of subjects: 175
Study 21467949 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.2 mmol/kg BW
Number of subjects: 175
Study 21467949 — intervention group
Group type: COMPARATOR
Intervention: Gadoteridol 0.2 mmol/kg BW
Number of subjects: 175
Study 21467949 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol and Gadoteridol
Number of subjects: 175
Study 19115651 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate-balanced fluid
Number of subjects: 20
Study 19115651 — intervention group
Group type: COMPARATOR
Intervention: Plasma-Lyte 148
Number of subjects: 20
Study 17052475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (Herbst appliance)
Number of subjects: 215
Study 17052475 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 215
Study 14600927 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (140 micro g/kg/min) with low level exercise protocol (300 MBq and 700 MBq Tc‐99m tetrofosmin for stress and rest respectively)
Number of subjects: 26
Study 14600927 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise (700 MBq Tc‐99m MIBI)
Number of subjects: 26
Study 14600927 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 26
Study 14600927 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise
Number of subjects: 26
Study 10573515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (13‐15 mg/kg daily)
Number of subjects: 37
Study 10573515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9051516 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyimide haptics
Number of subjects: 121
Study 9051516 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene (PP) haptics
Number of subjects: 121
Study 2070529 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin with hydrocortisone ear‐drops
Number of subjects: 64
Study 2070529 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone ear‐drops
Number of subjects: 64
Study 6859584 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg morphine epidurally
Number of subjects: 20
Study 6859584 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg morphine epidurally
Number of subjects: 20
Study 6859584 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg morphine epidurally
Number of subjects: 20
Study 31349042 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant radiation therapy (S+ART)
Number of subjects: 62
Study 31349042 — intervention group
Group type: COMPARATOR
Intervention: Surgical monotherapy (SM)
Number of subjects: 62
Study 31119692 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone (5 mg) administered in the fasting state as a single oral dose
Number of subjects: 24
Study 31119692 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone (5 mg) administered in the postprandial state as a single oral dose
Number of subjects: 24
Study 31119692 — intervention group
Group type: COMPARATOR
Intervention: Fasting intravenous administration of esaxerenone
Number of subjects: 24